Advertisement
Advertisement

IONS

IONS logo

Ionis Pharmaceuticals, Inc. Common Stock

75.78
USD
Sponsored
+0.72
+0.96%
May 21, 16:00 UTC -4
Closed
exchange

After-Market

76.20

+0.42
+0.56%

IONS Earnings Reports

Positive Surprise Ratio

IONS beat 29 of 42 last estimates.

69%

Next Report

Date of Next Report
Jul 28, 2026
Estimate for Q2 26 (Revenue/ EPS)
$195.29M
/
-$1.08
Implied change from Q1 26 (Revenue/ EPS)
-20.64%
/
+92.86%
Implied change from Q2 25 (Revenue/ EPS)
-56.80%
/
-254.29%

Ionis Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Apr 29, 2026, IONS reported earnings of -0.56 USD per share (EPS) for Q1 26, beating the estimate of -0.92 USD, resulting in a 39.67% surprise. Revenue reached 246.09 million, compared to an expected 199.54 million, with a 23.33% difference. The market reacted with a +4.25% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -1.08 USD, with revenue projected to reach 195.29 million USD, implying an increase of 92.86% EPS, and decrease of -20.64% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
logo
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
logo
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
logo
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
logo
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
logo
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-
Actual
-$0.07
Surprise
-
logo
Traws Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.75
Actual
-$0.53
Surprise
+29.78%
logo
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
logo
AIM ImmunoTech Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.37
Actual
-$0.56
Surprise
-52.53%
FAQ
For Q1 2026, Ionis Pharmaceuticals, Inc. Common Stock reported EPS of -$0.56, beating estimates by 39.67%, and revenue of $246.09M, 23.33% above expectations.
The stock price moved up 4.25%, changed from $71.78 before the earnings release to $74.83 the day after.
The next earning report is scheduled for Jul 28, 2026.
Based on 9 analysts, Ionis Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$1.08 and revenue of $195.29M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement